Accelerate Diagnostics is an in vitro diagnostics company. The company's Accelerate Pheno? system utilizes genotypic technology to identify (ID) infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial and fungal cells are resistant or susceptible to a particular antimicrobial. The Accelerate PhenoTest? BC Kit, which is the test kit for the system, provides ID and AST results for patients suspected of bacteremia or fungemia, both conditions with morbidity and mortality risk. The Accelerate Pheno? system comprises of a robotic pipettor for fluidic manipulation, an optical system, and an imaging system.

Anixa Biosciences is a biotechnology company focused on using the body's immune system to diagnose, treat and prevent cancer. The company's subsidiary, Anixa Diagnostics Corporation, develops Cchek?, a platform for non-invasive blood tests for the early detection of cancer. The company's subsidiary, Certainty Therapeutics, Inc., develops immuno-therapy drugs against cancer. The company has focused on the development of a treatment for ovarian cancer. The company is also engaged in limited patent licensing activities in the area of encrypted audio/video conference calling.

Cadence is a bank holding company. The company is engaged in commercial lending to middle-market customers and provide a range of commercial loans to middle-market commercial businesses, individuals and business owners. The company's loan portfolio includes commercial and industrial loans, residential real estate loans, commercial real estate loans and other consumer loans. The company also provides its customers a variety of deposit products, including checking accounts, savings accounts, money market accounts and other deposit accounts, through multiple channels, including its network of full-service branches, drive-thru branches, ATMs, ITMs, and its online, mobile and telephone banking platforms.

Cannae is a holding company engaged in managing and operating a group of companies and investments. The company's segments are: Restaurant Group, which consists of the operations of American Blue Ribbon Holdings, LLC and 99 Restaurants Holdings, LLC; Ceridian, which consists of the operations of the company's subsidiary, Ceridian HCM Holding, Inc., a global human capital management software company; T-System, which consists of the operations of the company's subsidiary, T-System Holdings, LLC, a provider of clinical documentation and coding solutions; and Corporate and Other, which consists of the company's share in the operations of controlled and uncontrolled portfolio companies.

CNA Financial is an insurance holding company. The company's property and casualty and remaining life and group insurance operations are primarily conducted by its subsidiaries. The company's insurance products primarily include commercial property and casualty coverages, including surety. The company's services include warranty, risk management information services and claims administration. The company's commercial property and casualty underwriting operations in the United States consists of field underwriting locations and centralized processing operations which handle policy processing, billing and collection activities and also act as call centers to support service.

Enterprise Products Partners is a provider of midstream energy services to producers and consumers of natural gas, natural gas liquids (NGLs), crude oil, petrochemicals and refined products. The company's midstream energy operations include: natural gas gathering, treating, processing, transportation and storage; NGL transportation, fractionation, storage, and export and import terminals; crude oil gathering, transportation, storage, and export and import terminals; petrochemical and refined products transportation, storage, export and import terminals, and related services; and a marine transportation business that operates primarily on the U.S. inland and Intracoastal Waterway systems.

Fate Therapeutics is a biopharmaceutical company. The company's off-the-shelf, induced pluripotent stem cells (iPSC)-derived cellular immunotherapy pipeline include: FT500, which is an off-the-shelf natural killer (NK) cell cancer immunotherapy for the treatment of solid tumors; and FT516, which is an off-the-shelf NK cell cancer immunotherapy. The company's other iPSC-derived cell product candidates include: FT301, an off-the-shelf, immuno-regulatory cell product candidate derived from a clonal master iPSC line. The company's allogeneic cellular immunotherapy pipeline include: ProTmune?, an investigational programmed cellular immunotherapy for use as an allogeneic hematopoietic cell transplantation cell graft.

HC2 Holdings is a holding company. Through its subsidiaries, the company operates in several segments including: Construction, which is a modeler, detailer, fabricator and erector of structural steel and heavy steel plate; Marine Services, which provides engineering and underwater services on submarine cables; Energy, which designs, builds, owns, acquires, operates and maintains compressed natural gas fueling stations for transportation vehicles; Telecommunications, which operates a telecommunications business including a network of direct routes and provides voice communication services; and Insurance, which provides long-term care, life, annuity, and other accident and health coverage.

J Alexander's Holdings is a holding company. Through its subsidiaries, the company owns and operates complementary upscale dining restaurants including: J. Alexander's, Redlands Grill, Lyndhurst Grill, Overland Park Grill and Stoney River Steakhouse and Grill. The J. Alexander's menu features prime rib of beef; hardwood-grilled steaks, seafood and chicken; pasta; salads; soups; and assorted sandwiches, appetizers and desserts. Stoney River is an upscale steakhouse concept that seeks to provide the quality and service of fine dining steakhouses at a lower price point. Redlands Grill provides a range of contemporary American cuisine featuring expanded menu offerings on a seasonal or rotational basis.

Pulse Biosciences is a bioelectric medicine company. The company is pursuing regulatory clearance to market CellFX? System (CellFX). The CellFX System utilizes its Nano-Pulse Stimulation? (NPS) technology to treat various applications for which an optimal solution remains unfulfilled. NPS is a proprietary technology that delivers nanosecond duration pulses of high amplitude electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue. The company's CellFX System allows for the adjustment of four key treatment parameters: pulse duration, pulse amplitude, pulse frequency, and the number of pulses, depending on the target tissue, application and desired treatment outcome.

Veritone is a provider of artificial intelligence (AI) computing solutions. The company has developed aiWARE?, a proprietary AI operating system that integrates and orchestrates an open ecosystem of performing cognitive engines. The company'saiWARE platform incorporates proprietary technology to integrate and intelligently orchestrate a variety of cognitive engine capabilities to mimic human cognitive functions. The company also operates a full service media advertising agency. The company's services include media planning and strategy, advertisement buying and placement, campaign messaging, clearance verification and attribution, and custom analytics.